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INTRODUCTION
Gastric neuroendocrine cells constitute about one percent ofthe volume ofthe oxyn-
tic mucosa. Ultrastructual studies have identified at least six distinct cell types in the
endocrine cell population (Table 1). Enterochromaffin-like (ECL)b cells are the most
numerous, constituting about 30 percent ofthe endocrine cell population, followed by P-
cells andD-cells (somatostatin cells) 24percentand 22percentrespectively (Table 2). The
endocrine cells are mainly located in the middle and lower third ofthe mucosal thickness.
The vast majority ofthese cells are randomly interspersed between the parietal and chief
cells lining the oxyntic glands [1-3]. Occasionally endocrine cells can also be identified
between mucosal neck cells in the superficial third ofthe mucosa as well as in association
with nerve fibers and Schwann cells in the laminapropria. Even though these various cell
types have a random spatial distribution, it is of interest that the ECL-cells are preferen-
tially located adjacent to the chiefcells and that their cell density within the mucosa nor-
mally shows little regional variation [3, 4].
Available evidence supports the origin of the gastric endocrine cells from the same
stemcells, located in the upperneckregion (the "renewal" zone) ofthe gastric gland from
which superficial/foviolar, mucous-neck, chief, parietal and pyloric/cardial gland cells
take origin [5]. In the pyloric-type mucosa, in humans, gastrin (G-cells) is usually con-
centrated in the deep mucous-neck and upper mucous-gland zonejust below the renewal
zone of the glands. The G-cells of the pyloric mucosa have been found to be renewed
through replication ofother gastrin cells as well as from undifferentiated progenitor cells
ofthe renewal zone and then migrate downwards together with mucous-gland cells [6, 7].
Mature ECL-cells have recently been shown not to divide (N. Wright, personal commu-
nication), therefore renewal should take place from the progenitor cells ofthe upper neck
region. Gastrin, argyrophil, argentaffin and mucous cells have been found to be intimately
admixed in endocrine-exocrine pyloric adenocarcinomas [8, 9]. Moreover, "amphicrine"
muco-endocrine cells may occur in gastric microcarcinoidosis and adeno-carcinoma [10].
During human fetal development endocrine cells first appear in the immature, glyco-
gen-rich gastric epithelium (at 9 to 10weeks) as smallproto-endocrine cells with scattered
ribosomes, reduced glycogen content, aboundant mitocondria, microfilaments and a few
small round secretory granules resembling those ofP-cells. By the 10th week, fairly dif-
ferentiated EC-, D- and GLI-cells havebeen observedbyimmunocytochemistry andultra-
structural studies. Pyloric G-cells and oxyntic ECL-cells appear later around the 14th
week. Besides typical vesicular granules with the coarsely granually content, ECL-cells
display dense solid, elongated granules resembling those of EC-cells or small round
homogenous granules resembling those ofP- or Dl-cells [11].
aTo whom all correspondence should be addressed: Kjell Oberg, M.D, Ph.D., Professor, Head
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Table 1. Neuroendocrine cells ofthe gastric mucosa.
Cell types Percent ofendocrine cell
(human oxynitic mucosa) population mean ± SD
ECL-cells 30 ± 9
P-cells 24 ± 7
D (somatostatin) cells 22 ± 4
D1 cells 9 8
EC-cells 7 5
X cells < 1
Non-granulated cells 8 ± 4
D'Adda et al. 1989
Table 2. Neuroendocrine cells ofthe gastric mucosa.
Cell types Percent ofendocrine
(human pyloric gland area) cell population
G-cells 40-60
EC-cells 20-40
D-cells 10-20
P-cells 1-5
Socia et al. 1989.
Neuroendocrine cells of the gastric mucosa are identified by the argyrophil staining
technique ofGrimelius, which identifies all oxyntic endocrine cells except forthe D-cells.
The Sevier-Munger argyrophil technique selectively stains the ECL-cells and a small subset
of the EC- and Dl-cells [12]. All the endocrine cells of the gut mucosa can be stained by
immunohistochemical technique using such markers of neuroendocrine differentiation as
chromogranin A, neuron specific enolase (NSE) and synaptophysin. Immuno-
histochemical techniques using antibodies against secretorial products of endocrine cells
have now been accepted and replaced many of the old histochemical techniques.
However, this technique is applicable only when the secretory products of a particularly
cell type is known and present in detectable amounts. One ofthe secretory products ofthe
ECL-cell, histamine, is displaying such a problem where immunohistochemical visual-
ization ofECL-cells requires special procedures such as freeze-drying, vapor-fixation and
cryostat sectioning [12].
ECL-CELLS
In humans, the ECL-cells are normally confined to the oxyntic mucosa ofthe stomach
where they constitute its predominant endocrine cell type [1, 13]. Scattered randomly in the
lower and intermediate third ofthe mucosal gland, these cells are preferentially associated
with chiefcells. The ECL-cells areessentially identified withchromograninAimmunohisto-
chemical staining together with the Sevier-Munger argyrophil technique. At the ultra-
structural level the ECL-cells show typical secretory granules showing electron dense
granules and also electron-lucent vesicles [14]. One ofthe most significant biological charac-
teristics ofthe ECL-cells is their sensitivity to the trophic influence ofgastrin. These cells,
therefore frequently undergo hyperplasia in chronically hypergastrinemic states [14].
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Table 3. Secretory products from neuroendocrine gastric cells.
ECL cells: Chromogranin A (splice products)
Chromogranin B
Synaptophysin
Histamin
Histidine decarboxylase (HDC)
Calbindin
(Gastrocalcin)
G-cells Gastrin
D-cells Somatostatin
Other pp
Serotonin
Calcitonin
HCG-ax subunits
SECRETORIAL PRODUCTS FROM NEUROENDOCRINE GASTRIC CELLS
The different secretory products from neuroendocrine gastric cells that have been
identified today are listed in Table 3. The main secretory products of the ECL-cells are
chromogranin A and histamine but also chromogranin B, synaptophysin, histidine decar-
boxylase (HDC) and serotonin [15, 16] can be identified. It has also been claimed that the
ECL-cells can produce calbindin, the 28KD calcium binding protein [17, 18]. Another
agent that is involved in calcium homeostasis, called gastrocalcin has been reported by
Ha.kanson et al. [19]; however, it has not yet been biochemically characterized. Finally,
the ECL-cells are also able to produce the alpha subunits of human choronic
gonadotrophin, particularly in situations with hyperplasia or malignant transformation.
The other cell types, G-cells, are producing gastrin and the D-cells, somatostatin. Other
known secretorial products from the gastric endocrine cells are pancreatic polypeptide,
serotonin, PYY and calcitonin.
CHROMOGRANINS/SECRETOGRANINS
These proteins, which are acidic polypeptides, found ubiquitously in the soluble
matrix of dense-core secretory granules in neurons and endocrine cells. The so-called
"granins" include chromogranin A and B and secretogranin II or chromogranin C. The
granins have been proposed to play multiple roles in the secretory process. Intracellularly,
granins play a role in targeting peptide hormones and neurotransmitters to granules ofthe
regulated pathway by virtue oftheir ability to aggregate in the low-pH, high calcium envi-
ronment ofthe trans-Golgi network [20-23]. One ofthe mostimportant secretory products
from the ECL-cells is chromogranin A (CgA). Although CgA was isolated already in the
end of 1960s, the biological function ofthis glycoproteins is not yet established. In Table
4, some ofthe biological functions are listed. Some conserved features ofthe mature CgA
protein are polyglutamic acids, calcium-binding sites and several pairs of basic amino
acids (Figure 1). The first two features are important for its intracellular function, and the
latter characteristics suggested thatpeptides couldbe released from the molecule by precursor
processing enzymes. Several biological active peptides are encoded within this chromo-
granin A molecule (Figure 1) such as vasostatins (CgA1-76, CgAI-113), pancreastatin
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Table 4. Chromogranin A.
General biological properties:
I. Regulation of secretory granule function:
a. Binding ofcalcium
b. Osmotic regulation
II. Participation in the secretory process
III. Precursor ofbiologically active peptides
IV. Antibacterial effects
(CgA248 301) and parastatin (CgA347 419). Putative receptors for CgAand its fragments are
believed to be G-protein-coupled receptors, which are pertussion toxin sensitive [24].
Biological effects ofunprocessed CgAinclude stimulation ofbrain micro-glialcells and
enhanced NO-synthetase activity and antibacterial effects [25]. Pancreastatin is known to
inhibit insulin release [26] and 14C-amino-purine uptake (histamine stimulated) in parietal
cells [27] and has also been described to abrogate the growth ofnormal pancreas and pan-
creatic cancer [28]. Parastatin has been reported to inhibit PTH secretion [24, 29, 30].
One ofthe major sources for circulating CgA is the ECL cells in the oxyntic mucosa
(nmol concentration) [31]. It has also been demonstrated that CgA is secreted from most
neuro-endocrine tumors and act as an important tumor marker [32, 33]. However, in
patients with gastrin-producing tumors, which are stimulating the ECL-cells ofthe oxyntic
mucosa, the main source ofchromogranin Ais not the gastrinoma but the ECL-cells [31].
In a recent study from Borch and co-workers [34], plasma chromogranin A correlated to
endocrine cell density in the fundic mucosa and also to serum gastrin concentrations in
patients with chronic atrophic gastritis type A. Furthermore, chromogranin A is increased
in all patients with gastric carcinoids irrespectively oftype, but the type III (nonA-CAG)
gastric carcinoid presents significantly higher levels of chromogranin A than type I and
type II gastric carcinoids, both ofthem related to gastrin hypersecretion (to be published).
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Figure 1. Biochemical structure ofthe chromogranin A molecule. Arrows denote dibasic cleav-
age sites. AI(A9 indicate polyclonal antibodies directed against different portions of the molecule.
CST, chromostatin; PANCST, pancreastatin; PARAST, parastatin.
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It has been speculated over the years whether chromogranin A is circulating as an
intact molecule orifitis spliced atdibasic cleavage sites. Wehaverecently generated nine
specific antibodies to various regions ofthe chromogranin Amolecule (Figure 1), and we
could demonstrate that a significant splicing ofthe molecule is occurring. Most frequently
was a fragment elevated detected by the antibody A3, which is directed to the C-terminal
part of vasostatin 1-113. This fragment is also increasing during tumor progression and
decreasing during successful treatment (to be published). We have previously reported
that chromogranin A is an independent marker ofprognosis for midgut carcinoid patients
in amultivariate analysis [35]. Therefore, the observation ofincreasing circulating levels of
the vasostatin 1-113 in patients with progressive disease could indicate a growth promoting
activity by this splice product. The vasostatins (CgAI-76, CgA1-113) have suppressive
effect on vasoconstrictorresponses in humanblood vessels [36], and abinding protein has
been identified in membranes of culture calf aorta cells. Furthermore, the vasostatin has
also been reported to mediate autocrine inhibition of parathyroid hormone release and a
binding protein ofsimilarmolecular sizeto that inthe calfaortacells has been characterized
in isolated bovine parathyroid cells [24]. Recently, Marchisio and co-workers have shown
that vasostatin 1-76 is stimulating cell adhesion through interaction with the integrins [37].
SUMMARY
The ECLcell is the most common cell type in the oxyntic mucosa ofthe stomach. It is
producing a number ofpeptides and amines where histamine and chromogranin A seems to
be the most important and abundant products. Recent data indicate a direct correlation
between ECL-cell mass andcirculating chromograninAlevels. ChromograninAand its splice
products mightserve as growthpromoting agents inECL-cellhyperplasiaorgastric carcinoids.
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